(April 9, 2019) On April 9, Guangzhou Wondfo Biotech Co., Ltd.. (“Wondfo ” or “Company”, Stock Code: 300482) released 2019 years Q1 business results forecast in the evening, the company initially estimated 2019 Q1 attributed to the shareholders of listed companies net profit of 6,622.58million Yuan to 7 , 4.5041 million yuan, up 20% to 35% from the same period last year, it continues to maintain a rapid growth momentum.
 
Q1 in 2019, the company continued to promote the global distribution of sales channels, relying on continuous high-intensity research and investment, guiding the innovation of technology Platform and Testing project, and constantly enriching the product line and optimize the product structure, creating high-quality products to drive the rapid and steady growth of performance. Specifically, the first quarter of the domestic flu outbreak led to the rapid growth of domestic colloidal gold platform product sales revenue, while the heart markers, inflammatory factors represented by the immunofluorescence platform sales revenue continued to maintain rapid growth, the continued rapid growth of sales revenue ensured a solid increase in the company’s net profit.
 
From 2017 to 2019, domestic influenza infection cases showed a clear upward trend. Wondfo Bio’s Influenza Virus Detection Kit uses colloidal gold immunochromatography and has the exclusive H7N9 Avian Influenza Test Kit product in China. The influenza project is the most comprehensive in the country and has taken the crown in the Ministry of Science and Technology’s influenza testing product evaluation. Wondfo Bio’s Influenza Virus Detection Kit features high sensitivity, fast detection speed, and can produce results in 15 to 20 minutes, which is suitable for on-site screening of hospitals and prevention and control units; the product is high specificity, prepared by influenza virus nucleoprotein (NP) monoclonal antibody, it has good reactivity for human Influenza A virus (including H7N9) with different subtypes of viruses and different strains.
 
Wondfo Bio’s Influenza Virus Detection Kit is in a leading position in the industry. Many domestic top three hospitals have regarded Wondfo Bio’s Influenza Virus Detection Kit as their first choice. In addition, Wondfo influenza products are also widely used in influenza detection, epidemic prevention and control, and large-scale activities. The rapid growth of sales of influenza detection product has boosted the sales revenue of the domestic colloidal gold platform.
 
Wondfo Bio’s Influenza Virus Detection Kit is in a leading position in the industry. Many domestic top three hospitals have regarded Wondfo Bio’s Influenza Virus Detection Kit as their first choice. In addition, Wondfo influenza products are also widely used in influenza detection, epidemic prevention and control, and large-scale activities. The rapid growth of sales of influenza detection product has boosted the sales revenue of the domestic colloidal gold platform.
 
With the gradual development of new technology platforms, the continuous increase of new projects on existed platforms and the global expansion in the sales area, Wondfo Biotech will repay its shareholders with sustained and steady performance growth.